Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and ...

Using chronological age cut-offs—such as 60 years—to divide patients with acute myeloid leukemia (AML) for clinical trials ...

A family was devastated after a baby's "ordinary cold" turned out to be a rare blood cancer. Four-month-old Melody developed ...

The FDA has approved two targeted menin inhibitors for the treatment of relapsed/refractory NPM1-mutated acute myeloid ...

The regimen of bexmarilimab and azacitidine (Vidaza) demonstrated a highly promising efficacy profile with a manageable ...

CR or mCR in 86% of patients within the first 12 months - Venetoclax-resistant secondary AML transformed from CMML responds to lenzilumab BURLINGAME, CA / ACCESS Newswire / November 4, 2025 / Taran ...

Developed by Ascentage Pharma, lisaftoclax is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors. Lisaftoclax is ...

Phase 1a of the trial examined dose escalation of IO-202 as a monotherapy and in combination with azacitidine. Phase 1b of the trial studied dose expansion data of IO-202 in combination with ...

Syndax has received approval from the Food and Drug Administration for a treatment for a type of acute leukemia. The biopharmaceutical company said Friday the approval is for its Revuforj therapy to ...

Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients—and found a potential way to overcome that resistance. Team ...

Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients – and found a potential way to overcome that resistance. Team ...